STOCK TITAN
  1. Home
  2. News
  3. ZOM

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated news page for Zomedica (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zomedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zomedica's position in the market.

News
Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET
Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) will be hosting a Virtual Investor Day event to discuss its portfolio of innovative products, manufacturing facilities, recent business developments, and financial position. The event will provide an overview of the company's capabilities and key drivers of future growth, followed by a live question-and-answer session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
conferences
-
News
Open Letter to Zomedica Shareholders from your Chief Executive Officer
Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) announced an open letter from CEO Larry Heaton to shareholders regarding the upcoming reverse split vote. The letter encourages shareholders to do their own due diligence and vote FOR the reverse split. The company offers point-of-care diagnostics and therapeutic products for equine and companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
-
News
Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference
Rhea-AI Summary
Zomedica Corp. CEO, Larry Heaton, to participate in fireside chat and one-on-one meetings with investors at Lytham Partners 2024 Investor Select Conference. The webcasted fireside chat will take place at 10:15am ET on Thursday, February 1, 2024, and can be accessed on the Company's website or directly at a provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences
News
Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split")
Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) reported record revenue of over $25 million for 2023, marking a 32% increase from 2022. The company expects revenue for the fourth quarter of 2023 to exceed $7 million, driven by strong performance in therapeutic and diagnostic product lines. Cash, cash equivalents, and available-for-sale securities are expected to be over $100 million at December 31, 2023. Zomedica CEO, Larry Heaton, highlighted the company's momentum in 2023, including acquisitions, product launches, and manufacturing improvements. The company introduced formal financial guidance for 2024, expecting revenue in the range of $31 to $35 million, an increase of approximately 40% over 2023. Additionally, Zomedica will seek approval for an 80-1 reverse stock split at a Special Meeting on February 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
stock split
-
News
Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of Shareholders on February 28, 2024
Rhea-AI Summary
Zomedica Corp. (ZOM) to Host Business Update Call on January 17, 2024, to Discuss Preliminary 2023 Revenue, Cash Position, and Share Consolidation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
conferences
-
News
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
Rhea-AI Summary
Zomedica Corp. (ZOM) announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients treated for musculoskeletal disease. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available in Frontiers in Veterinary Science. CSU is also evaluating the effectiveness of PulseVet therapy for slowing the progression of canine osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
News
Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
Rhea-AI Summary
Zomedica Corp. (NYSE American: ZOM) announced the commercial launch of three new assays: Canine Pancreatic Lipase (cPL), Cobalamin (B12), and Folate for the TRUFORMA® In-Clinic Biosensor Testing Platform. The company aims to provide faster diagnostic solutions, streamline workflow, and increase practice profitability for veterinarians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.53%
Tags
none
-
News
Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners
Rhea-AI Summary
Zomedica Corp. (NYSE American: ZOM) announced new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners. The study showed that shock wave therapy successfully treated barrel racing horses with Exercise Induced Pulmonary Hemorrhage (EIPH) and asthmatic horses. The company remains committed to advancing animal care through innovation and research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
Rhea-AI Summary
Zomedica Corp. (ZOM) to attend Noble Capital Markets' 19th Annual Emerging Growth Equity Conference. CEO Larry Heaton to present a Company overview and business update at 2:30 p.m. ET on December 5, 2023. A high-definition video webcast of the presentation will be available the following day on the Company's investor website and as part of a complete catalog of presentations available at Noble Capital Markets' conference website and on Channelchek.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences acquisition
News
Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) will attend the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28, 2023. CEO Larry Heaton will present a Company overview and business outlook at 10:30 a.m. ET. The live webcast of the presentation will be available on the Corporate website. The management team will also host one-on-one meetings with institutional investors at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
conferences
Stock ZOM logo
Zomedica Corp

NYSE:ZOM

ZOM Rankings

#4072 Ranked by Market Cap
#3990 Ranked by Stock Gains
N/A Ranked by Dividends

ZOM Stock Data

132.29M
963.34M
1.59%
8.89%
6.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Ann Arbor

About ZOM

zomedica (nyse american:zom) (tsx-v:zom) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. with a team that includes clinical veterinary professionals, it is zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.